Congrong Runtong Oral Liquid in the Treatment of Functional Constipation (Yang-deficiency Type)

A Randomized, Double-blind, Dose-exploration, Parallel-controlled, Multicenter Phase II Clinical Study of Congrong Runtong Oral Liquid in the Treatment of Functional Constipation (Yang-deficiency Type)

Using a placebo as a control, this study aims to preliminarily evaluate the clinical efficacy of Congrong Runtong oral liquid for the treatment of functional constipation (Yang-deficiency type), explore the optimal dosage of Congrong Runtong oral liquid for functional constipation (Yang-deficiency type) to provide a basis for dosage selection in Phase III clinical trials, and observe the safety of clinical use of Congrong Runtong oral liquid.

Study Overview

• Status: Completed
• Conditions: Functional Constipation
• Intervention / Treatment: Drug: Congrong Runtong oral liquid; Drug: Placental Congrong Runtong oral liquid

• Study Type: Interventional
• Enrollment (Actual): 180
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Dongcheng
    • Beijing, Dongcheng, China, 100010
      • Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Meets the Rome IV diagnostic criteria for functional constipation;
2. Meets the TCM diagnostic criteria for Yang-deficiency type constipation;
3. Aged between 18 and 70 years (inclusive);
4. Has undergone colonoscopy and has been diagnosed with either no abnormalities or non-adenomatous polyps (size not exceeding 0.5 cm, no more than 3) or has undergone polypectomy for more than 1 month and the pathological examination confirms no high-grade intraepithelial neoplasia within 12 months of colonoscopy examination in a tertiary grade A hospital
5. Less than 3 complete spontaneous bowel movements per week during the 2-week run-in period;
6. Voluntarily participates in the trial and signs an informed consent form.

Exclusion Criteria:

1. Patients with constipation caused by organic lesions of the rectum or colon (such as tumors, inflammatory bowel disease, anal fissure, intestinal adhesions, intestinal tuberculosis) leading to intestinal stenosis;
2. Patients with constipation caused by other systemic organic diseases, such as congenital megacolon, neurological disorders (such as autonomic neuropathy, cerebrovascular disease, etc.), mental disorders, metabolic endocrine disorders (such as hypothyroidism, diabetes mellitus with fasting blood glucose > 8.6mmol/L or with complications), muscular diseases (such as amyloidosis, dermatomyositis), etc.;
3. Patients whose drug-induced constipation cannot be ruled out by the investigators；
4. Patients with alarm signs judged by the investigator and unable to exclude malignant lesions by colonoscopy in the past three months;
5. ALT or AST ≥ 1.5 times the upper limit of the normal value, or Scr > upper limit of the normal value;
6. Patients allergic to the composition of the ingredients of the Cenruong Runtong oral solution or bisacodyl;
7. Pregnant or breastfeeding women, or women planning to become pregnant;
8. Patients who have participated in other clinical trials in the past 3 months;
9. Other situations judged by the investigator as inappropriate for participation in this trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Congrong Runtong oral liquid high-dose group; Congrong Runtong oral liquid, 2 bottles (1g herb content per bottle) per dose, three times a day	Drug: Congrong Runtong oral liquid; Congrong Runtong oral liquid：component "total glycosides of Cistanche" extracted and refined from the traditional Chinese medicine Cistanche deserticola
Experimental: Congrong Runtong oral liquid low-dose group; Congrong Runtong oral liquid, 2 bottles (0.5g herb content per bottle) per dose, three times a day	Drug: Congrong Runtong oral liquid; Congrong Runtong oral liquid：component "total glycosides of Cistanche" extracted and refined from the traditional Chinese medicine Cistanche deserticola
Placebo Comparator: Placebo group; Congrong Runtong oral liquid, 2 bottles (0g herb content per bottle) per dose, three times a day	Drug: Placental Congrong Runtong oral liquid; Placental Congrong Runtong oral liquid

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete Spontaneous Bowel Movement (CSBM) response rate within 8 weeks of treatment	CSBM response: the patient meets the CSBM weekly response at least 50% of the time during the weeks of drug treatment (e.g., 4/8 weeks). Weekly response: The patient has at least 3 CSBMs per week and has an increase of at least one CSBM compared to baseline, which is considered a weekly response. Overall CSBM response rate = CSBM response number / total observed number of people × 100%"	Examination will be performed after 8 weeks of treatment.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The occurrence of CSBM within the first 24 hours of starting treatment	Calculate the number of CSBM during the first 24 hours of treatment	Evaluation will be performed after 24 hours of treatment.
Changes in the number of bowel movements (BM)compared to baseline at 2, 4, 6, and 8 weeks	The patient recorded the number of BMs every day using a diary card, and the weekly number of BMs was the total of the seven days	Evaluation will be performed at baseline and after2，4，6，8 weeks of treatment.
Changes in the number of spontaneous bowel movements (SBM)compared to baseline at 2, 4, 6, and 8 weeks	The patient recorded the number of SBMs every day using a diary card, and the weekly number of SBMs was the total of the seven days	Evaluation will be performed at baseline and after2，4，6，8 weeks of treatment.
Changes in the fecal characteristics score (using the Bristol Stool Form Scale) compared to baseline at 2, 4, 6, and 8 weeks	Bristol Stool Form Scale： Type 1 Separate hard lumps, like nuts. Type 2 Sausage-shaped but lumpy. Type 3 Like a sausage or snake but with cracks on its surface. Type 4 Like a sausage or snake, smooth and soft. Type 5 Soft blobs with clear-cut edges. Type 6 Fluffy pieces with ragged edges, a mushy stool. Type 7 Watery, no solid pieces. The 1-7 types correspond to scores of 1-7 respectively.	Evaluation will be performed at baseline and after2，4，6，8 weeks of treatment.
Changes in the degree of difficulty in passing stools score (using the Likert scale) compared to baseline at 2, 4, 6, and 8 weeks	The Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire uses a Likert scale grading system for rating the severity of constipation symptoms, which is divided into five levels of severity: 0, 1, 2, 3, and 4.	Evaluation will be performed at baseline and after2，4，6，8 weeks of treatment.
The average number of CSBMs per week	The average number of CSBMs per week is calculated by dividing the total number of CSBMs during the observation period by the number of observation weeks (8 weeks)	Examination will be performed after 8 weeks of treatment.
The average number of SBMs per week	The average number of SBMs per week is calculated by dividing the total number of SBMs during the observation period by the number of observation weeks (8 weeks)	Examination will be performed after 8 weeks of treatment.
The average fecal characteristic score per week (using the Bristol Stool Chart)	The stool consistency score for each week is calculated by dividing the sum of all stool consistency scores for that week by the total number of bowel movements during that week.The average stool consistency score per week is calculated by dividing the sum of all weekly stool consistency scores by the number of observation weeks (8 weeks).	Examination will be performed after 8 weeks of treatment.
The use of rescue medication	Calculate the total number of rescue medication doses taken during the treatment period	Examination will be performed after 8 weeks of treatment.
The changes in TCM syndrome scores compared to baseline at 4 and 8 weeks of treatment	The TCM syndrome score of functional constipation consists of 5 questions, and the total scores are ranging from 0 to 24 with higher scores indicating more severe disease.	Examination will be performed at baseline and after 4,8 weeks of treatment.
Changes in the Patient Assessment of Constipation Quality of Life (PAC-QOL) score compared to baseline at 4 and 8 weeks of treatment	Calculate the total PAC-QOL score and the change in scores for the physiological, psychosocial, worries, and satisfaction domains compared to baseline	Examination will be performed at baseline and after4，8 weeks of treatment.

Collaborators and Investigators

• Sponsor: Beijing Hospital of Traditional Chinese Medicine

Study record dates

Study Major Dates

• Study Start (Actual): March 29, 2023
• Primary Completion (Actual): April 1, 2024
• Study Completion (Actual): April 1, 2024

Study Registration Dates

• First Submitted: March 26, 2023
• First Submitted That Met QC Criteria: March 26, 2023
• First Posted (Actual): April 7, 2023

Study Record Updates

• Last Update Posted (Actual): October 28, 2024
• Last Update Submitted That Met QC Criteria: October 25, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Signs and Symptoms, Digestive; Constipation; Yang Deficiency
• Other Study ID Numbers: KANION-CRRT-2022

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No